Kala Bio shares surge 18.37% premarket after appointing Dr. Saeid Babaei to evaluate clinical assets and AI development opportunities.

Kala Bio Inc. surged 18.37% in premarket trading following the announcement that it has engaged Dr. Saeid Babaei as Senior Scientific Advisor to evaluate its clinical and molecular assets, including its proprietary MSC Secretome platform. The collaboration aims to leverage AI-enabled analytics and digital health tools to explore precision development opportunities and reassess potential indications, which could unlock new commercial and scientific value. This strategic move aligns with Kala Bio’s broader focus on AI-driven research and the fast-growing MSC secretome market, suggesting a renewed emphasis on innovation and asset optimization.